363 related articles for article (PubMed ID: 31997802)
1. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.
Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
Neural Regen Res; 2020 Aug; 15(8):1432-1436. PubMed ID: 31997802
[TBL] [Abstract][Full Text] [Related]
2. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.
Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327
[TBL] [Abstract][Full Text] [Related]
3. Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.
Goulding SR; Lévesque M; Sullivan AM; Collins LM; O'Keeffe GW
Mol Neurobiol; 2021 Jul; 58(7):3405-3416. PubMed ID: 33713017
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR; Anantha J; Collins LM; Sullivan AM; O'Keeffe GW
Neural Regen Res; 2022 Jan; 17(1):38-44. PubMed ID: 34100424
[TBL] [Abstract][Full Text] [Related]
5. Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.
O'Keeffe GW; Hegarty SV; Sullivan AM
Neuronal Signal; 2017 Apr; 1(2):NS20170027. PubMed ID: 32714578
[TBL] [Abstract][Full Text] [Related]
6. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
7. BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons.
Hegarty SV; Sullivan AM; O'Keeffe GW
Mol Cell Neurosci; 2013 Sep; 56():263-71. PubMed ID: 23831389
[TBL] [Abstract][Full Text] [Related]
8. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
O'Keeffe GW; Sullivan AM
Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
[TBL] [Abstract][Full Text] [Related]
9. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.
Hegarty SV; O'Keeffe GW; Sullivan AM
Neural Regen Res; 2014 Oct; 9(19):1708-11. PubMed ID: 25422631
[TBL] [Abstract][Full Text] [Related]
10. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
Mazzocchi M; Wyatt SL; Mercatelli D; Morari M; Morales-Prieto N; Collins LM; Sullivan AM; O'Keeffe GW
Front Cell Dev Biol; 2019; 7():191. PubMed ID: 31572723
[TBL] [Abstract][Full Text] [Related]
11. Endocytosis contributes to BMP2-induced Smad signalling and neuronal growth.
Hegarty SV; Sullivan AM; O'Keeffe GW
Neurosci Lett; 2017 Mar; 643():32-37. PubMed ID: 28188849
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
13. Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.
Hegarty SV; Collins LM; Gavin AM; Roche SL; Wyatt SL; Sullivan AM; O'Keeffe GW
Neuromolecular Med; 2014 Jun; 16(2):473-89. PubMed ID: 24682653
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
Akerud P; Alberch J; Eketjäll S; Wagner J; Arenas E
J Neurochem; 1999 Jul; 73(1):70-8. PubMed ID: 10386956
[TBL] [Abstract][Full Text] [Related]
15. BMP/SMAD Pathway Promotes Neurogenesis of Midbrain Dopaminergic Neurons
Jovanovic VM; Salti A; Tilleman H; Zega K; Jukic MM; Zou H; Friedel RH; Prakash N; Blaess S; Edenhofer F; Brodski C
J Neurosci; 2018 Feb; 38(7):1662-1676. PubMed ID: 29321139
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
Voutilainen MH; Arumäe U; Airavaara M; Saarma M
FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
[TBL] [Abstract][Full Text] [Related]
17. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells.
Jordan J; Böttner M; Schluesener HJ; Unsicker K; Krieglstein K
Eur J Neurosci; 1997 Aug; 9(8):1699-709. PubMed ID: 9283824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
